Silkim Pharma
CEO & Founder: Dror Chevion
Stage: Pre-Clinical
Year Established: 2017
The company licensed the right to commercialize the technology from Yissum, the TTO of the Hebrew University. These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. The PLATFORM members show 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases (and anecdotal human cases).
